Odyssey of a cancer nanoparticle: From injection site to site of action

被引：304

作者：

Nichols, Joseph W. ^{[1
]}

Bae, You Han ^{[2
]}

机构：

[1] Univ Utah, Dept Bioengn, Salt Lake City, UT 84108 USA

[2] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84108 USA

来源：

NANO TODAY | 2012年 / 7卷 / 06期

关键词：

Drug delivery; Nanomedicine; Cancer; EPR; Extravasation; Diffusion; Tumor heterogeneity; Multidrug resistance; PEGYLATED LIPOSOMAL DOXORUBICIN; TUMOR-ASSOCIATED MACROPHAGES; PHASE-III TRIAL; SOLID TUMORS; MONOCLONAL-ANTIBODIES; MACROMOLECULAR THERAPEUTICS; INTERSTITIAL PRESSURE; EXTRACELLULAR-MATRIX; POLYMERIC MICELLES; ENDOTHELIAL-CELLS;

D O I：

10.1016/j.nantod.2012.10.010

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

No chemotherapeutic drug can be effective until it is delivered to its target site. Nano-sized drug carriers are designed to transport therapeutic or diagnostic materials from the point of administration to the drug's site of action. This task requires the nanoparticle carrying the drug to complete a journey from the injection site to the site of action. The journey begins with the injection of the drug carrier into the bloodstream and continues through stages of circulation, extravasation, accumulation, distribution, endocytosis, endosomal escape, intracellular localization and - finally - action. Effective nanoparticle design should consider all of these stages to maximize drug delivery to the entire tumor and effectiveness of the treatment. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：606 / 618

页数：13

共 114 条

[1] Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis [J].

Akinc, A ;

Thomas, M ;

Klibanov, AM ;

Langer, R .

JOURNAL OF GENE MEDICINE, 2005, 7 (05) :657-663

[2] Elemental tomography of cancer-cell spheroids reveals incomplete uptake of both Platinum(II) and Platinum(IV) complexes [J].

Alderden, Rebecca A. ;

Mellor, Howard R. ;

Modok, Szabolcs ;

Hall, Matthew D. ;

Sutton, Stephen R. ;

Newville, Matthew G. ;

Callaghan, Richard ;

Hambley, Trevor W. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (44) :13400-+

[3] Ligand-targeted therapeutics in anticancer therapy [J].

Allen, TM .

NATURE REVIEWS CANCER, 2002, 2 (10) :750-763

[4]

American Cancer Society, 2012, Cancer Facts and Figures 2012

[5]

[Anonymous], SCIENCE

[6]

[Anonymous], UND CHEM GUID PAT FA

[7] American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer [J].

Azzoli, Christopher G. ;

Baker, Sherman, Jr. ;

Temin, Sarah ;

Pao, William ;

Aliff, Timothy ;

Brahmer, Julie ;

Johnson, David H. ;

Laskin, Janessa L. ;

Masters, Gregory ;

Milton, Daniel ;

Nordquist, Luke ;

Pfister, David G. ;

Piantadosi, Steven ;

Schiller, Joan H. ;

Smith, Reily ;

Smith, Thomas J. ;

Strawn, John R. ;

Trent, David ;

Giaccone, Giuseppe .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6251-6266

[8] Docetaxel-related side effects and their management [J].

Baker, Jackie ;

Ajani, Jaffer ;

Scotte, Florian ;

Winther, Dorte ;

Martin, Miguel ;

Aapro, Matti S. ;

von Minckwitz, Gunter .

EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2009, 13 (01) :49-59

[9] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[10]

BOUCHER Y, 1990, CANCER RES, V50, P4478

← 1 2 3 4 5 6 7 8 9 10 →